International (Europe)

First-Line Approval Received for Abelcet in Spain

Published in AIDS Weekly, February 17th, 1997

Abelcet (amphotericin B lipid complex injection) has received approval in Spain as first-line treatment of patients with candidiasis.

Abelcet is a proprietary antifungal agent developed by The Liposome Company, Princeton, New Jersey. Fourteen countries have approved Abelcet for the treatment of various severe systemic fungal infections. Abelcet was previously approved in October 1995 in Spain for the second-line treatment of systemic fungal infections.

Spain has joined the United Kingdom, Italy, Ireland, Denmark, and Austria as countries that have approved Abelcet as first-line therapy for candidiasis. Greece has approved Abelcet for first-line...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-02-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry